Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2023; 13(5): 107-113

Simpor leaf extract (Dillenia suffruticosa Martelli) induced apoptosis of the MCF-7 and HepG2 cell lines

Sri Rahayu, Jungshan Chang, Atin Supiyani, Arief Prasetiyo.


Cancer is a malignant tumor with characteristics of uncontrolled cell growth, poor metastasis, leading to the dysfunction of organs and death of patients. Many efforts have been made, including the exploration of natural products. The purpose of this study was to determine the cytotoxicity of the Dillenia suffruticosa leaf extract against the cell lines MCF-7 and HepG2. The method used is an experimental research design with a completely randomized design. The treatment group consisted of the leaf extract of 500, 1,000, 2,000, 5,000, and 9,000 ppm for the brine shrimp lethality test (BSLT). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) test used 10, 15, 20, 25, and 50 ppm concentrations and control (without extract). The data on the BSLT test was determined by analyzing the lethal concentration 50 (LC50) value using the probit analysis, while the MTT test was determined by analyzing the IC50 and ONOVA test. The BSLT test results showed an LC50 value of 5,221 ppm, which means that the leaf extract is not toxic. Simpor leaf extract (D. suffruticosa) induces apoptosis of the MCF-7 and HepG2 cell lines. Giving a concentration of 50 ppm as the best in inhibiting MCF-7 with an IC50 value of 52.39, while a concentration of 25 ppm was seen on HepG2 with an IC50 value of 88.52. It can be concluded that D. suffruticosa shows cytotoxicity against the cell lines MCF-7 and HepG2 and can be used as a candidate for breast and liver cancer treatment.

Key words: Cytotoxicity, BSLT, Simpor Dillenia, Leaf, Cell Lines MCF-7, Cell Lines HepG2

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.